Sotatercept, when added to standard therapy, dramatically lowers the risk of death, lung transplantation, or hospitalization in patients with advanced, high-risk pulmonary arterial hypertension (PAH).
The ZENITH phase 3 trial shows a hazard ratio of 0.24 for the composite primary endpoint, signaling significant clinical benefit.
Sotatercept’s efficacy extends to delaying clinical worsening and improving functional outcomes in both intermediate and high-risk PAH populations.
Adverse events, while notable (epistaxis, telangiectasia), were generally manageable and did not outweigh the clinical benefits.
Clinical Background and Disease Burden
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.